Short Bowel Syndrome Market Report 2026

The short bowel syndrome market size has grown rapidly in recent years. It will grow from $3.08 billion in 2025 to $3.53 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to increasing prevalence of short bowel syndrome, limited treatment options historically, reliance on parenteral nutrition, rise in gastrointestinal surgeries, growing hospital awareness.

The short bowel syndrome market size is expected to see rapid growth in the next few years. It will grow to $6.02 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to development of novel therapeutics, increasing availability of home infusion services, personalized treatment approaches, integration of microbiome therapies, increasing clinical trials for SBS interventions. Major trends in the forecast period include rise in parenteral nutrition solutions, increasing development of intestinal rehabilitation therapies, adoption of novel surgical interventions, growing focus on gut microbiome modulation, expansion of patient support programs.

The growing prevalence of gastrointestinal diseases is expected to drive the growth of the short bowel syndrome market in the coming years. Gastrointestinal diseases encompass a wide range of disorders affecting the digestive system, including conditions involving the stomach, intestines, liver, and pancreas, often resulting in impaired digestion and reduced nutrient absorption. The increasing occurrence of these diseases is largely attributed to unhealthy dietary patterns that negatively affect gut health and promote inflammation. Gastrointestinal disorders can lead to short bowel syndrome when surgical removal of damaged intestinal sections becomes necessary, ultimately reducing the intestine’s absorptive capacity. For example, in September 2023, according to the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on improving outcomes for patients with Crohn’s disease and ulcerative colitis, more than 320,000 people in Canada were living with inflammatory bowel disease in 2023, representing a prevalence of 825 per 100,000 population. With prevalence projected to rise by 2.44% annually, approximately 1.1% of the population, or 470,000 Canadians, is expected to be affected by IBD by 2035. Therefore, the increasing prevalence of gastrointestinal diseases is contributing to the growth of the short bowel syndrome market.

Companies operating in the short bowel syndrome market are concentrating on advancing innovative medical treatments, including therapies for intestinal failure, to offer improved therapeutic options and enhance patient outcomes. Intestinal failure is a severe condition in which the small intestine is unable to absorb sufficient nutrients, fluids, and electrolytes to sustain adequate nutrition and hydration. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare company, released new data from studies assessing apraglutide in adults with short bowel syndrome and intestinal failure. As a next-generation GLP-2 analog, apraglutide showed potential to improve intestinal absorption and reduce dependence on parenteral nutrition. These results highlight the therapy’s efficacy, safety, and long-term benefits, underscoring Ironwood’s focus on developing innovative solutions for gastrointestinal disorders.

In May 2024, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, partnered with Inspire, a patient community platform, to enhance understanding of patient experiences and challenges associated with managing complex gastrointestinal conditions. This collaboration is intended to utilize real-world patient insights through multidisciplinary research to identify unmet needs, improve patient support, and encourage innovation in treatment strategies for short bowel syndrome. Inspire is a US-based online health and wellness community that connects patient engagement with real-world data platforms.

Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc.

North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the short bowel syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the short bowel syndrome market by increasing the cost of imported nutritional formulations, GLP-2 analogs, infusion products, and specialty medical supplies required for patient management. Hospital pharmacies and specialty pharmacies in Asia-Pacific and Europe are particularly affected, leading to higher therapy costs for patients requiring long-term nutritional and drug support. These pressures can limit adoption of advanced biologic and intravenous therapies. At the same time, tariffs are encouraging local production of nutritional and injectable therapies, improving supply continuity in the short bowel syndrome market.

The short bowel syndrome market research report is one of a series of new reports that provides short bowel syndrome market statistics, including short bowel syndrome industry global market size, regional shares, competitors with a short bowel syndrome market share, detailed short bowel syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the short bowel syndrome industry. This short bowel syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Short bowel syndrome (SBS) is a malabsorption condition resulting from the loss or dysfunction of a substantial portion of the small intestine, which leads to reduced absorption of nutrients and fluids. It commonly causes diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of symptoms varies based on the length of intestine remaining and its capacity to adapt. SBS can have a major impact on overall health and requires careful dietary and medical management.

The main types associated with short bowel syndrome include glucagon-like peptide (GLP-2), growth hormone, and glutamine. Glucagon-like peptide-2 (GLP-2) is an intestinal hormone that plays an important role in improving nutrient absorption, stimulating intestinal growth, and reducing gut inflammation, making it a key therapeutic target for conditions such as short bowel syndrome. Diagnosis involves physical examinations, blood tests, fecal fat tests, imaging procedures, and other methods, while treatment includes nutritional therapy, medications, surgery, and transplantation. These therapies are distributed through channels such as hospital pharmacies, specialty pharmacies, and others.

The short bowel syndrome market consists of revenues earned by entities by providing services such as medical care, diagnostic testing, nutritional support, and ongoing patient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The short bowel syndrome market also includes sales of oral rehydration solutions, antidiarrheal medications, proton pump inhibitors, antimotility agents, bile acid binders, antimicrobials, and specialized enteral nutrition formulas. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.